

Form PTO-1449 (modified)

Atty. Docket No.:

CLFR:029USD1

Serial No.:

10/676,725

List of Patents and Publications for Applicant's

Applicant:

Michael ROSENBLUM

INFORMATION DISCLOSURE STATEMENT

Filing Date:

October 1, 2003

Group:

1642

(Use several sheets if necessary)

U.S. Patent Documents


See Page 1

Foreign Patent Documents

See Page 1-2

Other Art

See Page 2-3



U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A50	2005/0214307	09/29/05	Rosenblum <i>et al.</i>	424	178.1	08/26/04
	A51	2002/0090374	07/11/02	Yarkoni <i>et al.</i>	724	178.1	03/02/98
	A52	5,621,083	04/15/97	Better <i>et al.</i>	530	391.9	04/18/95
	A53	5,830,880	11/03/98	Sedlacek <i>et al.</i>	514	44	04/18/97
	A54	5,851,829	12/22/98	Marasco <i>et al.</i>	435	328	03/30/95
	A55	6,140,066	10/31/00	Lorberboum-Galski <i>et al.</i>	435	7.23	03/24/98
	A56	6,197,528	03/06/01	Wu <i>et al.</i>	435	7.2	02/12/99
	A57	6,218,165	04/17/01	Estell <i>et al.</i>	435	221	02/23/99
	A58	6,309,873	10/30/01	Torrens Madrazo <i>et al.</i>	435	216	08/13/99
	A59	6,531,133	03/11/03	Lorberboum-Galski <i>et al.</i>	424	197.11	01/27/99
	A60	6,639,054	10/28/03	Alibhai <i>et al.</i>	530	350	01/05/01
	A61	6,703,020	03/09/04	Thorpe <i>et al.</i>	424	178.1	04/28/00
	A62	7,083,957	08/01/06	Rosenblum <i>et al.</i>	435	183	02/12/02

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B44	EP 0893493	01/27/99	Europe	German (English Abstract)
	B45	WO 00/26406	05/11/00	WIPO	English
	B46	WO 00/42179	07/20/00	WIPO	German (English Abstract)
	B47	WO 02/074979	09/26/02	WIPO	English
	B48	WO 02/42420	05/30/02	WIPO	English
	B49	WO 90/013649	11/15/90	WIPO	English
	B50	WO 98/37901	09/03/98	WIPO	English

25761645.1

EXAMINER:

/Laura B. Goddard/

DATE CONSIDERED:

04/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

Form PTO-1449 (modified)		Atty. Docket No.: CLFR:029USD1	Serial No.: 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Michael ROSENBLUM	
		Filing Date: October 1, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-3</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B51	WO 99/29721	06/17/99	WIPO	English
	B52	WO 99/43840	09/02/99	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C186	Ardekani <i>et al.</i> , "Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies," <i>Current Therapeutic Res.</i> , 62:803-819, 2001.
	C187	Arora, "Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells," <i>Cancer Research</i> , 59:183-188, 1999.
	C188	Better <i>et al.</i> , "Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties," <i>J. Biol. Chem.</i> , 269:9644-9650, 1994.
	C189	Clarke <i>et al.</i> , "Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential," <i>Biochemical Pharmacology</i> , 62:1311-1336, 2001.
	C190	Fischer <i>et al.</i> , "Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice," <i>Carcinogenesis</i> , 22(1):83-88, 2001.
	C191	Fitzgerald <i>et al.</i> , "Why toxins!," <i>Seminars in Cancer Biology</i> , 7:87-95, 1996.
	C192	Hamawy <i>et al.</i> , "Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies," <i>Transplantation</i> , 68:693-698, 1999.
	C193	Ivanov, "Therapeutic monoclonal antibodies in oncology," <i>Medicinal Immunol.</i> , 3:268, 2001.
	C194	Johnson <i>et al.</i> , "Construction of an epitope vector utilising the diphtheria toxin B-subunit," <i>FEMS Microbiol. Lett.</i> , 146:91-96, 1997.
	C195	Liu <i>et al.</i> , "Mechanistic studies of a novel, human fusion toxin composed of vascular endothelial growth factor (VEGF) ₁₂₁ and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells," <i>Molecular Cancer Therapeutics</i> , 2:949-959, 2003.

25761645.1

EXAMINER: /Laura B. Goddard/

DATE CONSIDERED:

04/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

Form PTO-1449 (modified)	Atty. Docket No.: CLFR:029USD1	Serial No.: 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Michael ROSENBLUM	
	Filing Date: October 1, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-3</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C196	Liu <i>et al.</i> , "Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents," <i>Mol. Cancer Ther.</i> , 2:1341-1350, 2003
	C197	McGraw <i>et al.</i> , "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias," <i>Cancer Immunol. Immunother.</i> , 39:367-374, 1994.
	C198	Murray <i>et al.</i> , "Radioimmunoimaging in Malignant Melanoma Patients With the Use of Indium-111-labeled Antimelanoma Monoclonal Antibody (ZME-018) to High-molecular-weight Antigen," <i>NCI Monogr.</i> , 3:3-9, 1987.
	C199	Parakh <i>et al.</i> , "Cloning a single-chain analogue of the anti-melanoma monoclonal antibody ZME-018: Construction and testing of an antibody recombinant gelonin fusion toxin," <i>Proc. Am. Assoc. Cancer Res. Annual Meetings</i> , 36:488, 1995 (Abstract 2909).
	C200	Roscoe <i>et al.</i> , "Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin," <i>Infect. Immun.</i> , 62:5055-5065, 1994.
	C201	Rosenblum <i>et al.</i> , "Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells," <i>Cancer Immunol. Immunother.</i> , 42:115-121, 1996.
	C202	Sairam <i>et al.</i> , "Structural characterization of gelonin: evidence for separate antigenic and cytotoxic domains," <i>Biochemistry and Molecular Biology International</i> , 31:575-581, 1993.
	C203	Shoemaker <i>et al.</i> , "Application of a human tumor colony-forming assay to new drug screening," <i>Cancer Res.</i> , 45:2145-2153, 1985.
	C204	Stremovskii <i>et al.</i> , "Functional construction of anti-ferritin mini-antibody/ribonuclease," <i>Medicinal Immunol.</i> , 3:279, 2001.
	C205	Suhrbier <i>et al.</i> , "Role of single amino acids in the recognition of a T cell epitope," <i>J. Immunol.</i> , 147:2507-2513, 1991.
	C206	Wild <i>et al.</i> , "Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells," <i>Br. J. Cancer</i> , 83:1077-1083, 2000.
	C207	Yudina <i>et al.</i> , "Study of interaction between anti-HER-2/NEU-mini-antibodies with SKOV-3 ovarian adenocarcinoma cells," <i>Medicinal Immunol.</i> , 3:285, 2001.

25761645.1

EXAMINER: /Laura B. Goddard/	DATE CONSIDERED: 04/24/2008
------------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./